Its likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo Nordisks semaglutide is set to sit in second place
GLP-1 receptor agonists slow gastrointestinal transit time
However, we now know that glucagon is necessary to enable the pancreas to release optimal levels of insulin
Without a proper plan to gradually reduce your dose (called tapering or a down-titration schedule), you might end up regaining some of the weight youve lost
Great news for both patients, physicians and of course welcome news for Novo Nordisk now since FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)